Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study details a case of a 20-year-old woman with APECED syndrome and alopecia areata who experienced complete scalp hair regrowth and improved quality of life after nine months of ruxolitinib treatment, highlighting the drug's effectiveness for severe AA linked to AIRE gene mutation.

This study found that fluconazole increased water transport in renal cells via effects on aquaporin-2 channels, suggesting potential as a treatment for nephrogenic diabetes insipidus, though clinical trials are needed to confirm efficacy in humans.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

This review discusses the fermented wheat germ extract Avemar as a potential adjunctive therapy in cancer treatment, noting promising laboratory results, but reports limited human trial evidence for its clinical effectiveness.

In this case report, interferon-alpha treatment for a man with hemophilia and hepatitis C was associated with unexpected diffuse hair growth, likely caused by the medication.

In this case study, alopecia was observed as a possible side effect in a patient taking oral acyclovir for herpetic keratouveitis, which resolved after discontinuing the medication.

This report discusses the FDA's rejection of Aveed, a long-acting testosterone injection, due to safety concerns despite divided advisory committee opinions, without presenting new clinical data.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

Abatacept may help some people with alopecia areata regrow hair.

This review reports on the potential for deucravacitinib, an oral TYK2 inhibitor approved for psoriasis, to treat various immune-mediated diseases, with emerging research suggesting possible uses in neurodegenerative diseases and certain cancers.

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

This case report highlights significant improvement in a patient with severe alopecia areata who responded well to ivarmacitinib after a suboptimal response to another JAK inhibitor, tofacitinib, suggesting ivarmacitinib as a potential alternative for tofacitinib-refractory cases.

This report highlights Amvuttra's approval for hATTR amyloidosis as a more convenient RNAi therapy, and Olumiant's attention as the first systemic drug for hair loss among recent developments.

In this case report, researchers observed hair regrowth in a patient with alopecia universalis and psoriasis after treatment with deucravacitinib, a TYK2 inhibitor, though they note spontaneous regrowth cannot be ruled out and suggest further controlled studies to evaluate its effects on alopecia areata.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.

This review synthesizes current knowledge on acral vitiligo, highlighting its treatment resistance, psychosocial impact, and emerging therapies like JAK inhibitors, while identifying knowledge gaps and future research directions.

This study found that vinblastine's metabolites show binding affinities for receptors linked to nausea and alopecia, suggesting potential changes to its structure could minimize these side effects during chemotherapy.

In this multicenter study, belimumab effectively reduced disease activity in systemic lupus erythematosus patients with joint and skin manifestations, showing significant improvement in acute and subacute skin types earlier than in chronic types, while no significant benefit was observed for nonspecific skin manifestations.

This study found that a new peptide, Snakin-Z, from Ziziphus jujuba fruits, shows significant inhibitory effects on AChE and BChE enzymes and strong antioxidant activity, suggesting potential benefits for Alzheimer's disease treatment.

This review discusses various therapeutic properties of bee venom, including its potential against cancer, infections, and inflammatory diseases, but notes limitations in clinical application due to variability and safety concerns, calling for further research.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This study found that bis-benzylisoquinoline and Amaryllidaceae alkaloids, especially aromoline, show potential as antiviral agents, suggesting they could serve as foundations for developing new treatments against coronaviruses by enhancing the understanding of their structure-activity relationships.

In this study on mice, a baricitinib-loaded microneedle patch enhanced hair growth in alopecia areata lesions (68% vs control: 33%, p < 0.05), suggesting it may deliver treatment effectively and pain-free, with fewer systemic side effects.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

This study suggests that HDAC inhibitors, such as Vorinostat and Entinostat, could be effective in promoting hair regrowth in a mouse model of alopecia areata.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

In a mouse model study, transcutaneous auricular vagus nerve stimulation (taVNS) significantly reduced depigmentation in vitiligo, potentially through mechanisms that regulate oxidative stress and inflammation, indicating taVNS's promise as a therapeutic approach for this skin disorder.

This study reported that the novel topical serum REVIVV®, containing a blend of phytochemicals, significantly improved hair growth and reduced shedding in 150 participants with androgenetic alopecia after 8 weeks of use, while also being rated easy to use and prompting plans for continued use.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This study reports on a new semantic annotation approach used to identify substances in MEDLINE abstracts responsible for adverse drug reactions, with promising performance shown by a prototype system.